1.External Quality Analysis of Quality Indicators on Specimen Acceptability
Yuan-Yuan YE ; Wei WANG ; Hai-Jian ZHAO ; Feng-Feng KANG ; Wei-Xing LI ; Zhi-Ming LU ; Wei-Min ZOU ; Yu-Qi JIN ; Wen-Fang HUANG ; Bin XU ; Fa-Lin CHEN ; Qing-Tao WANG ; Hua NIU ; Bin-Guo MA ; Jian-Hong ZHAO ; Xiang-Yang ZHOU ; Zuo-Jun SHEN ; Wei-Ping ZHU ; Yue-Feng L(U) ; Liang-Jun LIU ; Lin ZHANG ; Li-Qiang WEI ; Xiao-Mei GUI ; Yan-Qiu HAN ; Jian XU ; Lian-Hua WEI ; Pu LIAO ; Xiang-Ren A ; Hua-Liang WANG ; Zhao-Xia ZHANG ; Hao-Yu WU ; Sheng-Miao FU ; Wen-Hua PU ; Lin PENG ; Zhi-Guo WANG
Journal of Modern Laboratory Medicine 2018;33(2):134-138,142
		                        		
		                        			
		                        			Objective To analyze the status of quality indicators(QI) on specimen acceptability and establish preliminary qual ity specification.Methods Web based External Quality Assessment system was used to collect data of laboratories partici pated in "Medical quality control indicators in clinical laboratory" from 2015 to 2017,including once in 2015 and 2017 and twice in 2016.Rate and sigma scales were used to evaluate incorrect sample type,incorrect sample container,incorrect fill level and anticoagulant sample clotted.The 25th percentile (P25) and 75th percentile (P75) of the distribution of each QI were employed to establish the high,medium and low specification.Results 5 346,7 593,5 950 and 6 874 laboratories sub mitted the survey results respectively.The P50 of biochemistry (except incorrect fill level),immunology and microbiology reach to 6σ.The P50 of clinical laboratory is 4 to 6σ except for incorrect sample container.There is no significant change of the continuous survey results.Based on results in 2017 to establish the quality specification,the P25 and P75 of the four QIs is 0 and 0.084 4 %,0 and 0.047 6 %,0 and 0.114 2 %,0 and 0.078 4 %,respectively.Conclusion According to the results of the survey,most laboratories had a faire performance in biochemistry,immunology and microbiology,and clinical laboratory needs to be strengthened.Laboratories should strengthen the laboratory information system construction to ensure the actual and reliable data collection,and make a long time monitoring to achieve a better quality.
		                        		
		                        		
		                        		
		                        	
2.Thinking of research and development on new traditional Chinese medicine drugs for external use
Chao-Jun ZHU ; Jia-Kang L(U) ; Zhao-Hui ZHANG
The Chinese Journal of Clinical Pharmacology 2017;33(6):574-576
		                        		
		                        			
		                        			Traditional Chinese medicine (TCM) for external use in the treatment of surgical disease has good clinical effect and security,even played a unique effect.At present,surgical department of TCM lack of external application drug.The hospital's own production of external use drug cannot meet the clinical needs,seriously restricting the development of surgical department of TCM.Under the background of attaching great importance to new drug innovation research and development in our country,in the caseof clinical demand of external application drug increases year by year,it is imperative to promote external application drug research and development.This article summarizes the clinical application situation of external application drug,sums up the opportunity and the challenge of new drug research and development,analyses the difficulties and problems in research and development,and the countermeasures were discussed.
		                        		
		                        		
		                        		
		                        	
3.Study on Mechanism of Loganin Against AGEs Induced GMCs Injury via AGEs/RAGE/SphK1 Pathway
Xing L(U) ; Hui-Qin XU ; Gao-Hong L(U) ; Yun-Hao WU ; Yu-Ping CHEN ; Hong-Sheng SHEN ; Guo-Ying DAI ; Kang XU
Journal of Nanjing University of Traditional Chinese Medicine 2017;33(4):382-385
		                        		
		                        			
		                        			OBJECTIVE To study the mechanism of loganin,the effective componet of Cornus officinalis,on protecting the glomerulus mesangial cell (GMCs) injured by advanced glycation end products (AGEs).METHODS GMCs were divided into control,model (AGEs: 200mg/L),loganin (0.1,1,10μmol/L) groups.The cell proliferation,FN and COL-Ⅳ secretion,microstructure lesions,RAGE,SphK1,S1P and TGF-β protein expressions were measured.RESULTS AGEs induced cell proliferation,FN and COL-Ⅳ secretions,microstructure lesions,RAGE,SphK1,S1P and TGF-β protein expressions were suppressed by loganin.CONCLUSION Loganin can improve the AGEs induced GMCs injury by regulating the AGEs/RAGE/SphK1 signal pathway,and then ameliorate the diabetic nephropathy.
		                        		
		                        		
		                        		
		                        	
4.Present situation of research and development of traditional Chinese medicine orthopedics formula
Ai-Guo WANG ; Jia-Kang L(U) ; Fu-Shun GU ; Kun-Lun ZHENG
The Chinese Journal of Clinical Pharmacology 2017;33(13):1254-1256
		                        		
		                        			
		                        			Traditional Chinese medicine (TCM) orthopedics formula is an important part of the prevention and treatment of orthopedics disease,which has curative effect and the advantages of the whole regulation,but it needs to strengthen its clinical development and reasonable application in clinical.In this paper,by reviewing the current clinical present situation and some problems of the research and development about the TCM orthopedics formula,research and development direction were put forward:the source of prescription,the change of disease spectrum,the clinical location,the apphcation of toxic drugs and animal materials,and the quality control of clinical trials should be paid attentions to,hoping to provide some thoughts for the research and development of TCM orthopedics formula.
		                        		
		                        		
		                        		
		                        	
5.Discussion of clinical research on new Chinese herbal medicine is used to treat diabetic foot ulcers
Chao-Jun ZHU ; Jia-Kang L(U) ; Bei ZHOU ; Zhao-Hui ZHANG ; Kai-Jun YANG
The Chinese Journal of Clinical Pharmacology 2017;33(13):1257-1259
		                        		
		                        			
		                        			Diabetic foot ulcer (DFU) is one of the serious complications of diabetes.With high disability,high amputation rate,serious harm to the physical and mental health of diabetes patients.Traditional Chinese medicine drugs for external use has a certain effect and advantages for treatment of DFU.In this paper analyzes the clinical characteristics of DFU and the status of external drug application,and the necessity of research and development of traditional Chinese medicine for DFU treatment.In the article pointed out the difficulties and of the concerns in process of clinical trials for the DFU traditional Chinese medicine research and development.The preliminary recommendations are given in this article.
		                        		
		                        		
		                        		
		                        	
6.Research and evaluation of new drugs on traditional Chinese medicine and Chinese medicine in the treatment of knee osteoarthritis
Ai-Guo WANG ; Jia-Kang L(U) ; Fu-Shun GU ; Kun-Lun ZHENG
The Chinese Journal of Clinical Pharmacology 2017;33(14):1379-1381
		                        		
		                        			
		                        			Knee osteoarthritis (KOA) is a clinical common and frequent ly-occurring disease,traditional Chinese medicine (TCM) and Chinese medicine have certain advantages for patients in the treatment of early-middle period KOA.In this paper,by reviewingthe clinical feature,evaluation methods and present status of treatment of KOA,the evaluation of traditional Chinese medicine of KOA was proposed.the disease characteristics and clinical localization and clinical characteristics of TCM should be paid attention to,so as to select the evaluation method that can reflect the treatment of characteristics.
		                        		
		                        		
		                        		
		                        	
7.Interpretation of clinical research guidelines for new drugs of Chinese traditional medicine on influenza treatment
The Chinese Journal of Clinical Pharmacology 2017;33(14):1382-1384
		                        		
		                        			
		                        			Influenza (hereinafter referred to as "flu") guidelines is spe cifically defined to guide the clinical research for new drug of traditional Chinese medicine and the technical standards that the manager,applicant and researcher shall abide by.This article discusses the revision status of flue guidelines for a better understanding and aims to play a guiding role in the research for the new drug development of traditional Chinese medicine.
		                        		
		                        		
		                        		
		                        	
8.Research and evaluation of traditional Chinese medicine and Chinese medicine in the treatment of knee osteoarthritis
Ai-Guo WANG ; Jia-Kang L(U) ; Fu-Shun GU ; Kun-Lun ZHENG
The Chinese Journal of Clinical Pharmacology 2017;33(16):1610-1612
		                        		
		                        			
		                        			Knee osteoarthritis(KOA) is a clinical common and frequently -occurring disease,traditional Chinese medicine (TCM) and Chinese medicine has a certain advantage for patients in the treatment of early-middle period.In this paper,review the clinical feature,evaluation methods and present status of treatment of KOA,offer the evaluation of traditional Chinese medicine of KOA,should pay attention to the disease characteristics and clinical localization and clinical characteristics of TCM,select the evaluation method that it can reflect the treatment of characteristics.
		                        		
		                        		
		                        		
		                        	
9.Thinking of research and development on new traditional Chinese medicine drugs containing mercury for external use
Bei ZHOU ; Chao-Jun ZHU ; Jia-Kang L(U) ; Zhao-Hui ZHANG ; Xiang L(U)
The Chinese Journal of Clinical Pharmacology 2017;33(18):1847-1849,1852
		                        		
		                        			
		                        			The external medicine is an indispensable treatment of traditional Chinese medicine (TCM) surgery.The application of Hg is one of the characteristics of TCM surgery medicine for external use.This paper analyzes the present situation of clinical application of Hg and summarizes the common adverse reactions in the literature.The focus of the research on the development of new drugs containing Hg in traditional Chinese medicine is discussed.
		                        		
		                        		
		                        		
		                        	
10.Status quo and factors influencing smoking cessation in cigarette smoking patients with coronary artery disease
Tai-Yang LUO ; Tao LEI ; Xiao-Hui LIU ; Xue-Mei PENG ; Jun-Ping KANG ; Qiang L(U) ; Hai-Yun WANG ; Chang-Sheng MA
Chinese Journal of Cardiology 2011;39(5):406-409
		                        		
		                        			
		                        			Objective To investigate the status quo of smoking cessation and analyze factors influencing smoking cessation in cigarette smoking patients with coronary artery disease(CAD).Method A total of 350 smoking patients with CAD was surveyed by questionnaire,logistic regression analysis was performed to analyze factors influencing smoking cessation.Results Incidence of smoking cessation was 57.1%(200/350)in this cohort.Patients were divided into two groups,the elderlv(>65 years old,n=111)and the young group(≤65 years old,n=239).The smoking cessation rate in the elderlv group is significantly higher than in the young group(71.2%vs.50.6%,P<0.001).Aged patients and patients with high cultural level are easier to give up smoking.Logistic analysis showed that age≤65 years old (OR=2.336,P=0.004),low cultural level(OR=1.310,P=0.028),PCI(OR=0.261.P<0.001).coronary artery bypass graft(OR=0.107,P=0.004),total family income>4000 RMB/month (OR=1.828,P=0.003)are risk factors for failed smoking cessation.There are 76 patients smoking again in current smokers,most due to lack of self-control(76.3%).Compared to the elderly group,there is a higher proportion of smoking again due to the need of daily communication and work in the young group.Conclusions We still need to raise the awareness of smoking cessation for smoking patients with CAD.Following factors should be focused for tobacco control in CAD patients:younger age,lower cuItural level,not treated with PCI or CABG,patients with smoking family members.higher body mass index and higher total family income.
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail